Haleon plc (NYSE:HLN) Stock Position Lifted by Fielder Capital Group LLC

Fielder Capital Group LLC grew its holdings in shares of Haleon plc (NYSE:HLN) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,810 shares of the company’s stock after purchasing an additional 1,422 shares during the period. Fielder Capital Group LLC’s holdings in Haleon were worth $218,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Addison Advisors LLC boosted its stake in Haleon by 28.7% during the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after buying an additional 1,106 shares in the last quarter. Synovus Financial Corp lifted its holdings in Haleon by 0.8% in the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock valued at $1,575,000 after acquiring an additional 1,216 shares during the last quarter. Greenleaf Trust boosted its position in shares of Haleon by 8.4% during the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock valued at $164,000 after purchasing an additional 1,333 shares in the last quarter. Baron Wealth Management LLC boosted its position in shares of Haleon by 4.3% during the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after purchasing an additional 1,381 shares in the last quarter. Finally, Peapack Gladstone Financial Corp grew its stake in shares of Haleon by 3.2% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock worth $474,000 after purchasing an additional 1,390 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on HLN. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Stock Performance

Haleon stock opened at $9.81 on Friday. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The firm’s 50 day simple moving average is $9.59 and its 200-day simple moving average is $9.83. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $44.39 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, equities research analysts predict that Haleon plc will post 0.43 EPS for the current year.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.